Xolair (omalizumab) - Roche, Novartis
Tezspire (tezepelumab-ekko) - AstraZeneca, Amgen
Nucala (mepolizumab) - GSK
Fasenra (benralizumab) - AstraZeneca
Dupixent (dupilumab) - Sanofi, Regeneron
telikibart (GR1802) - Zhixiang (Shanghai) Pharma
http://www.ncbi.nlm.nih.gov/pubmed/41261303
 
Anne-Sophie Homøe; Christian K Pedersen; Christian Von Buchwald; Jens Even Tidemandsen; Kasper Aanæs; Marie Høxbro; Simon Høj; Vibeke Backer
 
Nov 20, 2025
 
Next